Optimizing DMARD Therapy in Rheumatoid Arthritis
A phase IV trial from Spain demonstrates that optimization of therapy by lessening biological DMARDs in rheumatoid arthritis (RA) may be feasible, with a low risk of flare.
News
Not all difficult-to-treat RA will have rapid radiographic progression
A study of radiographic outcomes in difficult-to-treat rheumatoid arthritis (D2T RA) and poly-refractory RA (pr-RA) show a subset in whom damage is rapid and in need of more aggressive therapy.
Sequencing DNA to find new lupus treatments
EurekAlert!
Associations in Rheumatology (10.3.2025)
Dr. Jack Cush reviews the news, journal reports and important associations in rheumatology from the past week on RheumNow.com.
Activity Trackers Can Predict RA Flares
MedPage Today
ILD in Juvenile Dermatomyositis: Moving Toward Better Outcomes
Juvenile dermatomyositis (JDM) is typically recognized for its striking skin rashes, vasculopathy, and muscle inflammation. Less visible, but equally significant, is lung involvement.
Hip Osteoarthritis Treated with Exercise plus Weight Loss Diet
An exercise and diet intervention study showed that while exercise improved hip pain, adding a weight loss diet to exercise did not change hip pain but improve most secondary outcomes.
Guselkumab FDA Approved for Pediatric Psoriasis and Psoriatic Arthritis
FDA announced yesterday that guselkumab (Tremfya) is approved for use in pediatric patients moderate to severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA) in children six years and older (weighing at least 40 kg).
Challenges diagnosing lung disease and ILD in pediatric patients
Children with juvenile idiopathic inflammatory myositis (JIIM) are at risk of developing lung disease, notably interstitial lung disease (ILD).
Lung Involvement in Pre-RA
When I see patients with RA-associated ILD, I’m often asked: “Are the lungs and joints really connected?” The answer is yes, and the connection extends further back than some may realize. While RA is defined by inflammation of the joints, extra-articular complications of the lung are well recognized. ILD has often been viewed as a complication of longstanding RA, but it can also appear before joint disease in a subset of patients.
Detection, Monitoring & Management of Autoimmune ILD
The American Journal of Managed Care has reviewed the approach to patients with interstitial lung disease (ILD); a significant cause of morbidity and mortality in those with systemic autoimmune rheumatic diseases (SARDs), including rheumatoid arthritis (RA), systemic sclerosis (SSc), and idiopath
How Does Your Garden Grow (9.26.2025)
Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Pool therapy, Fibrosis, NSIE's and what's best for knee OA.
What is IPAF?
Idiopathic Interstitial Pneumonia with Autoimmune Features - or IPAF - describes patients with interstitial pneumonia with autoimmune features, but they don’t meet a diagnosis of a CTD.
Polypharmacy Impairs Rheumatoid Arthritis Outcomes
A French early rheumatoid arthritis (RA) study has shown that polypharmacy (PP) was associated with significant lower treatment responses and more serious adverse events (SAEs).
Rheumatoid arthritis begins long before symptoms
EurekAlert!
Scientists have discovered that rheumatoid arthritis (RA) doesn’t start when the pain begins. It silently starts years earlier.The new research reveals that people at risk for RA experience dramatic immune system changes long before they feel symptoms.
